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1.1 Skeletal Muscle 
Skeletal muscle makes up approximately 40% of total body mass making it the most 
abundant tissue in the human body (Gransee et al., 2012). Skeletal muscle tissue 
comprises numerous multi-nucleated muscle cells, collectively known as muscle fibres, 
which work in a unitary fashion to support contraction. The endomysium, a protective 
layer made up of connective tissue, surrounds muscle fibres. Fibre bundles, known as 
fascicles, are covered with a connective tissue layer known as the perimysium. The 
epimysium coats bundles of fascicles (muscle) with a connective sheath (Lieber, 2002). 
Skeletal muscles have a striated appearance due to the highly organised arrangement 
of thick and thin filaments within myofibrils and due to the alignment of these 
myofibrils within each individual muscle fibre (McMahon, 1984; Lieber, 2002; Hall, 
2011). The contractile unit in skeletal muscle tissue is the sarcomere. Thick filaments 
are primarily composed of the protein myosin, while thin filaments contain the protein 
actin.  
 
Individual myofibrils within muscle fibres are surrounded by an intracellular membrane 
network known as the sarcoplasmic reticulum (SR). This structure plays a vital role in 
muscle contraction by regulating intracellular calcium (Ca2+) levels. Ca2+-dependent 
interaction of actin and myosin is the molecular basis resulting in muscle contraction 
and force generation (Plowman, 2017). Myosin plays a role in pulling thin filaments 
towards the centre of the sarcomere. 
 
The central nervous system controls skeletal muscle contraction. The activity of alpha 
motor neurons which synapse on skeletal muscle fibres is regulated by motor centres 
in the brain. These motor centres are responsible for controlling motor neuron activity 
in the ventral horns of the spinal cord (Gransee et al., 2012).  For skeletal muscle 
contraction to occur, motor neurons must fire an action potential to cause the alpha 
motor neuron release of acetylcholine. A conformational change in the 
dihydropyridine receptors (DHPRs) induces SR Ca2+ channel (ryanodine receptor) 
opening, which results in increased myoplasmic Ca2+ concentrations. This increase 
promotes muscle contraction through the exposure of myosin binding sites on thin 
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filaments. When myoplasmic Ca2+ is sequestered by Ca2+ ATPase in the SR, relaxation 
occurs. Excitation–contraction coupling (ECC) describes the rapid communication 
between electrical events occurring in the plasma membrane of skeletal muscle fibres 
and Ca2+ release from the SR. The prolonged elevation of intracellular Ca2+ results in 
sustained muscle contraction. 
 
1.1.1 Muscle Fibre Types 
Skeletal muscle fibre types can be classified based on their individual speed of 
contraction, myosin ATPase activity and enzymatic activity along the various glycolytic 
and oxidative pathways. The two basic skeletal muscle fibre types are fast twitch (type 
IIA & type IIB) and slow twitch fibers (type I). Myosin isoform expression dictates the 
speed of contraction as this influences ATPase activity. These fibres also differ in motor 
unit size, fibre diameter, metabolic activity, recruitment pattern and sensitivity to 
tetany (increased muscle tension due to repeated stimulation). Slow-twitch muscle 
fibres are typically recruited first, before fast-twitch muscle fibres, due to the greater 
excitability of the neurons which innervate them. Slow-twitch fibres also have a high 
oxidative capacity which supports sustained contractile activity. On the other hand, 
fast-twitch fibres typically have a high glycolytic capacity and a low oxidative capacity. 
For short periods of activity where high levels of force are required, the fast twitch 
fibres are better suited. Mitochondrial expression is believed to play a role in 
influencing enzymatic activity. Following denervation, skeletal muscle fibres typically 
atrophy. Muscle fibres rely on motor nerve activity for the maintenance of muscle fibre 
size. Skeletal muscle exhibits plasticity and regular growth of skeletal muscle occurs 
through the addition of more myofibrils and sarcomeres. 
 
1.1.2 Respiratory Muscle 
Each respiratory muscle serves to aid the primary function of the lungs, gas exchange. 
The lungs supply oxygen to the vasculature, and in exchange they remove carbon 
dioxide. Pump muscles are involved in ventilation (movement of air into the lungs), 
while airway muscles control both upper and lower airway calibre. Airway muscles 
comprise of skeletal (upper) and smooth (bronchi and trachea) muscles. Respiratory 
muscles can exhibit plasticity in order to functionally adapt to physiological stimuli 
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(Koeppen & Stanton, 2010; Gransee et al., 2012). Both the anatomy and composition 
of the upper airway muscles play important roles in performing tasks such as 
breathing, swallowing and speech (van Lunteren et al., 1987). Upwards of 20 different 
skeletal muscles have roles in both the control and maintenance of airway calibre 
(Boyd et al., 2004). 
 
1.1.3 Diaphragm 
The diaphragm is the primary pump muscle involved in ventilation, critical in 
maintaining respiratory homeostasis. The thoracic diaphragm is a sheet of skeletal 
muscle which extends across the bottom of the thoracic cavity. This C-shaped structure 
of muscle and fibrous tissue divides the chest cavity from the abdominal cavity. 
Innervation of the diaphragm muscle is supplied by the phrenic nerve, which is formed 
from the cervical nerves C3, C4 and C5. Diaphragm muscle spindles provide sensory 
input to the central nervous system and in turn can modulate motor output to the 
diaphragm along the phrenic nerve (Nair 2017). While the central portion of the 
diaphragm sends sensory afferents via the phrenic nerve, the peripheral portions of 
the diaphragm send sensory afferents via the intercostal (T5–T11) and subcostal 
nerves (T12). This muscle has a mixed fibre type composition (55% slow, 24% fast 
glycolytic and 21% fast oxidative fibers) allowing it to be resistant to fatigue (Polla et 
al., 2004). With the largest proportion of muscle fibres being slow, the diaphragm can 
remain one of the more active muscles in the body. Large diaphragmatic and external 
intercostal muscle contractions work in tandem to increase the size of the thoracic 
cavity and reduce intra-thoracic pressure, facilitating lung inflation. 
 
1.1.4 Intercostal Muscles 
Accessory muscles of breathing, such as the intercostal muscles have an important role 
in facilitating ventilation in health and disease especially during increased ventilatory 
demand. The intercostal muscle group encompasses a variety of muscles which are 
located between the ribs. These muscles serve to form and move the chest wall. 
Through contractions, these muscles expand and narrow the size of the thoracic cavity 
in order to facilitate breathing. The structure of these muscles is composed of three 
principal layers (each with different functions): 1) innermost intercostal muscle; 2) 
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internal intercostal muscle; 3) external intercostal muscle. External intercostal muscle 
facilitates quiet and forced inhalation. This layer of muscle is responsible for the 
elevation and bending of the ribs allowing them to open, thus expanding the 
dimensions of the chest cavity. The fibres of external and internal muscles run in 
opposite directions and are innervated by the ventral rami of thoracic spinal nerves. 




The genioglossus (GG) muscle plays a crucial role in both the defence and maintenance 
of upper airway patency (Remmers et al., 1978). The GG is one of the paired extrinsic 
muscles of the tongue which is fan-like in shape. The GG begins at the mental spine of 
the mandible and its insertions are the hyoid bone and the bottom of the tongue. The 
GG is innervated by the hypoglossal nerve. The GG receives its blood supply from the 
sublingual branch of the lingual artery, a branch of the external carotid artery. If 
sensory input and/or motor output become compromised, collapse of the airway can 
occur due to upper airway muscle hypotonia.   
 
1.1.6 Sternohyoid 
In addition to the GG, the sternohyoid (SH) muscles are essential pharyngeal muscles 
which are responsible for maintaining upper airway patency (Roberts et al., 1984; Van 
de Graaff et al., 1984; van Lunteren et al., 1987). These paired muscles connect the 
sternum and the hyoid bone and are located anterior and parallel to the trachea. 
During inspiration, upper airway dilator muscles exhibit phasic activity (Sauerland & 
Harper, 1976; Sherrey et al., 1986; Wiegand et al., 1990), while during expiration, 
upper airway constrictor muscles exhibit phasic activity (Kuna & Vanoye, 1997). 
Innervation of the SH is provided by the anterior rami of the 1st to 3rd cervical spinal 
nerves (C1 - C3) via the ansa cervicalis of the cervical plexus. The negative pressure 
generated by the diaphragm muscle during inspiration is sensed by mechano-receptors 
located in the upper airway, leading to increased activation of pharyngeal dilator 
muscles and increased tone of the upper airway musculature (Mathew, 1984). This is 
an important reflex for maintaining upper airway patency and mediating airflow for 
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gas exchange in the lungs. Occlusions of the airway seem to occur when there is 
reduced activity of pharyngeal dilator muscles (Remmers et al., 1978). The SH muscles 
move the hyoid bone anteriorly which stabilizes the upper airway to prevent collapse 
and maintain patency. Sternohyoid muscles are primarily composed of fast (type II B) 
muscle fibers sensitive to fatigue (Attal et al., 2000b). There is an inverse relationship 
between fatigue resistance and force production in muscle fibres (Schiaffino & 
Reggiani, 2011). There is a balance between the opposing actions of the diaphragm 
and upper airway pharyngeal muscle activity which must be finely regulated in order 
to maintain upper airway patency (Remmers et al., 1978; Attal et al., 2000a; White, 
2005). Thus, if either of the key respiratory muscles are compromised in any way, 
respiratory homeostasis will be challenged. 
 
1.2 Motor Units 
1.2.1 Henneman’s Size Principle 
Neuromuscular control of respiratory muscle is ultimately dependent on the 
physiological properties and function of respiratory muscle motor units. A motor unit 
is comprised of a single motor neuron together with the skeletal muscle fibres that it 
innervates. A collection of motor units in known as the motor ‘pool’. Different 
members of this motor pool work in tandem with one another to allow motor control 
of skeletal muscle (Sherrington, 1935). The multiple skeletal muscle fibres within a 
single motor unit are homogeneous (same muscle fibre type). When a motor unit is 
active, each fibre within the unit contracts producing an output of force. The number 
of muscle fibres innervated by a motor neuron varies from muscle to muscle; larger 
muscles typically contain a greater abundance of muscle fibres. Thus, the larger the 
number of muscle fibres, the greater the level of force generation. 
 
Motor units are typically categorised based on their mechanical and fatigability 
characteristics (Mantilla & Sieck, 2003). The four motor unit types are as follows: 1) 
Type S – slow twitch, fatigue resistant; 2) Type FR – fast twitch, fatigue resistant; 3) 
Type FInt – fast twitch, fatigue intermediate; and 4) Type FF – fast twitch, fatigable. In 
a similar fashion, muscle fibre types are also classified into four types based on myosin 
heavy chain composition or histochemical properties: 1) Type I (Slow oxidative, MHC 
 11 
Slow); 2) Type IIa (Fast oxidative/glycolytic, MHC2A); 3) type IIb (Fast glycolytic, MHC2B); 
and 4) type IIx (MHC2X) (Mantilla & Sieck, 2003).1.2.1 Henneman's Size Principle 
Pre-motor neurons located in the medulla provide rhythmic excitatory input to phrenic 
motor neurons in the cervical spinal cord. The central nervous system is responsible 
for the recruitment of motor neurons, typically recruiting smaller units first. This is 
captured in Henneman's size principle (Henneman et al., 1965), whereby Henneman 
and colleagues inferred that motor units are recruited in order of size, from smallest 
to largest. The magnitude of the load on the muscle determines the type of muscle 
fibres required and thus the motor units which require activation. Typically, small loads 
would first require the recruitment of slow twitch, low-force, fatigue-resistant muscle 
fibres. If necessary, these would be followed by the recruitment of the fast twitch, 
high-force, less fatigue-resistant muscle fibres which would typically be components 
of larger motor neurons. 
 
1.2.2 Rate Coding & Recruitment 
In terms of controlling the force output of respiratory muscle, the respiratory network 
employs two key mechanisms, motor unit spatial and temporal recruitment. Spatial 
recruitment involves the recruitment and activation of more motor units in order to 
produce a greater output of force. On the other hand, temporal recruitment, otherwise 
known as ‘rate coding’, speaks to the change in the frequency of activation of motor 
units.  
 
1.3 Control of Breathing 
The primary function of the respiratory system is to keep the partial pressure of carbon 
dioxide (PaCO₂), oxygen (PaO₂) and pH constant to maintain blood-gas homeostasis. 
Thus, it is crucial that sensory, central and motor signaling are constantly active. The 
integrated respiratory control system is composed of the central pattern generator 
(medulla), and central (medulla oblongata) and peripheral (aortic arch & carotid sinus) 
chemoreceptors. Peripheral chemoreceptors (carotid body) send afferent signals to 
the medulla via the carotid sinus nerve and the reflex response is evoked based on the 
levels of blood PaO2, PaCO₂ and pH.  
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1.3.1 Neural Control of Breathing 
Controlled ventilation involves a high level of timing and co-ordination. Motor neurons 
driving the pump muscles (facilitating inspiration and expiration) are located at various 
levels in the spinal cord. The diaphragm is innervated by the phrenic nerve (C3-C5), 
intercostal muscles by motor neurons in the thoracic spinal cord (T1-T12), and the 
abdominal muscles by motor neurons within the thoracic and lumbar regions of the 
spinal cord (T4-L3).  Motor neurons which innervate the upper airway muscles are 
typically located in the brainstem or upper cervical spinal cord. The larynx is innervated 
by the recurrent laryngeal nerves, pharyngeal muscles by the glossopharyngeal nerves 
and the pharyngeal branch of the vagus. The hypoglossal (XII) nerve innervates the GG 
muscle, which controls upper airway patency and governs tongue protrusion during 
inspiration, while the tensor veli palatini muscle (soft palate) is innervated by the 
mandibular branch of the trigeminal nerve and serves to maintain nasopharyngeal 
isthmus patency during inspiration.  
 
During inspiration, a dynamic reciprocal action exists between the glottis and 
respiratory pump muscles. The pump muscles (diaphragm and intercostal) contract 
and the glottis dilates (abduction). Upper airway pharyngeal muscles contract and 
dilate the pharynx, and the tongue is pulled forward facilitating airflow. Upper airway 
muscle movements precede diaphragm contraction (recurrent laryngeal and XII nerve 
activity precedes phrenic activity). Timing and control of these muscles can be 
modified by sensory feedback. Quiet expiration is a passive, but braked mechanism. 
This allows air to move out slowly, allowing a smoother transition between inspiration 
and expiration and mediating phonation. Diaphragm motor units can adapt to stimuli, 
by mediating an increase or decrease in motor unit activity. Remodelling of the 
neuromuscular system can lead to structural and physiological changes within the 
respiratory system. Motor neuron remodelling can occur also, such as dendritic 
branching or changes in somal surface area. Neuromuscular junction remodelling can 
occur, such as alterations at the pre- and post-synaptic membrane. In terms of 
myofibre remodelling, alterations in structural, mechanical and biochemical properties 
can occur. Adaptation or remodelling of the respiratory control system can be captured 
under the umbrella term of respiratory plasticity. 
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1.4 Respiratory Plasticity 
Plasticity can be described as the ability of an organism to make significant changes to 
itself based on its environment or external stimuli. Building on this, respiratory 
plasticity can be defined as the persistent change in the respiratory neural control 
network based on a prior experience (Johnson & Mitchell, 2002; Mitchell & Johnson, 
2003). These changes may involve functional and/or compositional adaptations. 
Recently, neuroplasticity has been considered as one of the building blocks of the 
respiratory control network (Feldman et al., 2003; Mitchell & Johnson, 2003), 
especially when considering pathophysiological conditions. In recent years, the field 
has explored the potential of harnessing both spontaneous and induced respiratory 
plasticity for the treatment of clinical disorders in which ventilatory control is impaired 
(Gonzalez-Rothi et al., 2015). The ‘crossed phrenic phenomenon’ demonstrates the 
phenomenon whereby the partial spontaneous functional recovery of phrenic motor 
output occurs post spinal hemi-section (Goshgarian, 2003). This has then been further 
examined after repeated cycles of chemostimulation through bouts of intermittent 
hypoxia (Vinit et al., 2009; Dale-Nagle et al., 2010; Lovett-Barr et al., 2012).  
 
Remarkably, spontaneous compensatory neuroplasticity is observed in animal models 
of clinical disorders such as motor neuron disease. In the rat model of amyotrophic 
lateral sclerosis (ALS), despite profound phrenic motor neuron death, a capacity to 
generate adequate tidal volume remains (Nichols et al., 2013). Motor neurone disease 
is a neurodegenerative disorder which is characterised by progressive neuronal 
atrophy, muscle weakness and paralysis (Mayeux et al., 2003). In terms of the 
respiratory system in ALS, motor neuron loss is a hallmark feature (Lyall et al., 2001). 
It is not surprising that patients with ALS suffer from significant ventilatory impairment 
and obstructive sleep apnoea (Fallat et al., 1979; Lyall et al., 2001; Stewart et al., 2001; 
Talakad N et al., 2009). Of note, this respiratory insufficiency does not truly develop 
until the later stages of disease progression which begs a lot of questions. Currently, it 
is not understood whether this respiratory insufficiency occurs due to the late onset of 
motor neurone death or not. Animal models of ALS display convincing evidence that 
breathing functional capacity is preserved until well after respiratory motor neuron 
atrophy has developed (Nichols et al., 2013). It has been seen at both human and 
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animal model level that despite significant neuropathology, and ultimately 
compromised phrenic motor output, breathing is still maintained. This considers the 
idea that intricate compensatory strategies must be at play in a do or die adaptation 
to preserve breathing capacity (Nichols et al., 2013; Nichols et al., 2015). The authors 
suggest that this strategy may have a four-pronged approach as follows: 1) enhanced 
central drive to functioning motor neurons; 2) active plasticity within said neurons; 3) 
enhanced plasticity at the level of the neuro-muscular junction (NMJ); and 4) alteration 
of demand from the diaphragm to less-used respiratory motor neuron pools.  
 
1.4.1 Central Drive Plasticity 
While inspiratory pattern formation and rhythm generation occurs at one location, in 
the ventrolateral medulla (Feldman et al., 2013), the regulation of central respiratory 
drive to respiratory motor units may occur at many sites. Central respiratory drive may 
be manipulated by various afferent sensory inputs (Feldman et al., 2013), such as 
carotid chemoreceptors (Kumar & Prabhakar, 2012), and pulmonary stretch receptors 
(Brouns et al., 2012). Central respiratory drive may be increased or reduced from 
sensory feedback at the level of the spinal cord (Aminoff & Sears, 1971). Muscle 
spindles respond to changes in muscle velocity and length. By invoking the myotatic 
reflex respiratory muscle spindles can protect the body from overstretched induced 
injury. These spindles stimulate reflexively a muscle contraction and maintain muscle 
tone in order to prevent fibre damage. Repeated stimulation of central or peripheral 
chemoreceptors can sometimes maintain an adequate level of breathing in disease 
states. 
 
1.4.2 Phrenic Motor Neuron Plasticity 
There are two forms of inducible spinal respiratory plasticity: 1) Phrenic motor 
facilitation and 2) phrenic long-term facilitation. These exhibit clear signs of 
augmented synaptic inputs to respiratory motor neurons (Dale-Nagle et al., 2010).  In 
animal models of spinal cord injury, following acute intermittent hypoxia, phrenic long-
term facilitation has shown the potential to increase phrenic motor output, improving 
respiratory motor neuron function. Furthermore, in animal models of contusion injury, 
a greater capacity for compensatory respiratory plasticity has been observed (Golder 
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et al., 2011; Lane et al., 2012). In these rodents, despite mid-cervical spinal injury with 
severe phrenic motor neuron impairment, breathing capacity resumes to normalised 
levels. This supports the idea of compensatory respiratory strategies outside the 
realms of brainstem control and/or motor neuron plasticity.   
1.4.3 Neuromuscular Junction Plasticity 
Respiratory plasticity may occur at various sites, including downstream of the 
respiratory motor neurons (Mantilla & Sieck, 2003). Hallmark features of 
neuromuscular and neurological disorders include NMJ deterioration and muscle fibre 
atrophy and necrosis. These pathologies may be as a result of, or worsened by, 
neuronal degeneration (Krakora et al., 2012). It is possible that compensatory 
mechanisms may be at play to delay this NMJ deterioration for as long as possible. 
Decreased action potentials and denervation is seen in rodent models of cervical 
contusion injury. Yet, remarkably, just 14 days after injury, there are signs of partial re-
innervation of diaphragm fibres (Nicaise et al., 2012). Structure-activity dynamics also 
exist between diaphragm muscle fibres and NMJs. Further to this, the recruitment of 
phrenic motor units may vary amongst a variety of behaviours (Mantilla & Sieck, 2011). 
There is evidence to suggest that respiratory plasticity at the level of the NMJ may play 
a key role in preserving respiratory capacity. However, this may be limited to the type 
of fibres/NMJ injured. 
 
 
1.4.4 Plasticity - Shifting the demands of respiratory motor neuron pools 
The final form of plasticity involves shifting the demands to other respiratory motor 
neuron pools. This shift may include the rotation of the demand to lesser compromised 
motor neuron pools or muscle fibres. This may involve switching from primary 
pathways (diaphragm) to other accessory pathways. It is established that intercostal 
muscles can maintain quiet breathing without diaphragm support (Maskrey et al., 
1992). Building on this, enhanced intercostal electromyogram (EMG) activity has been 
demonstrated in animals with bilateral phrenectomy, showing a possible mechanism 
of compensatory plasticity (Rice et al., 2011) during times of compromised 
diaphragmatic function. Additionally, intercostal motor plasticity is greater compared 
to phrenic motor plasticity in response to episodic hypoxia (Fregosi & Mitchell, 1994). 
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This opens the possibility for targeting and harnessing respiratory neuronal plasticity 




The dystrophin gene is currently the largest described human gene with its full-length 
RNA expression found mainly in skeletal and cardiac muscle with small amounts also 
being found in the brain (Falzarano et al., 2015). In total, the dystrophin gene spans 
greater than 2.5 million base pairs, making it close to 0.1% of the entire human genome 
(Muntoni et al., 2003). The structural protein dystrophin serves to anchor the 
extracellular matrix to the actin cytoskeleton via a protein complex spanning the 
sarcolemma. Dystrophin protects the sarcolemma from damage during muscle 
contraction and stress via F-actin binding to β-dystroglycan, with this interaction it can 
act as both a bridging and an anchoring protein (Cirak et al., 2011; Ogura et al., 2014). 
Dystrophin is part of a larger complex of proteins, making up the dystrophin associated 
protein complex (DAPC). When dystrophin is not present, muscle contraction places 
mechanical stress on the plasma membrane, which causes damage to muscle fibers in 
the absence of dystrophin and eventual necrosis (Gumerson & Michele, 2011). Muscle 
fibre regeneration does occur initially through satellite cells, however, when this 
regenerative capacity is exhausted (Ogura et al., 2014), fibrosis prevails and fatty tissue 
infiltrates which results in the loss of functional myofibres (Cros et al., 1989; Cirak et 
al., 2011).  
 
1.5.1 Dystrophinopathies 
Dystrophinopathies are a group of genetic conditions which can result in a spectrum 
of muscle weakness, varying from mild to severe. These disorders are inherited in an 
X-linked manner, meaning males are far more likely to experience symptoms in 
comparison to females. Duchenne muscular dystrophy (DMD) is characterised by 
profound skeletal muscle weakness and dilated cardiomyopathy. Becker muscular 
dystrophy (BMD) is another type of muscular dystrophy in which symptoms may 
present in a much milder form with a later onset compared to DMD. A longer life 
expectancy is typically seen in patients with BMD. 
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1.5.2 DMD 
DMD is the most severe disorder of the muscular dystrophies (Emery, 1991) and has 
the highest incidence of the dystrophinopathies. It is one of the most common rare 
genetic diseases occurring in 1:3300 live male births (Scheuerbrandt et al., 1986; Chung 
et al., 2016). DMD is a fatal X-chromosome linked recessive disorder caused by the 
deletion or alteration of the dystrophin gene (Hoffman et al., 1987). The dystrophin 
gene may be altered as follows: deletions (65%), duplications (6-8%), minor mutations 
(10%), and other re-arrangements. In patients with DMD, the dystrophin protein is not 
expressed. DMD is named after the term ‘dystrophy’, meaning degeneration from 
disease and from Guillaume Duchenne, a French neurologist (Parent, 2005). DMD is 
typically diagnosed at age four, when the initial symptoms begin to appear (Pane et al., 
2013). Despite extensive research into DMD, there is no effective treatment to date. 
Patients are commonly wheelchair-bound by age 12 (Wagner & Berry, 2008) and have 
a significantly reduced life expectancy (Yiu & Kornberg, 2008).   
 
1.5.3 Pathophysiology of DMD 
A key characteristic of DMD is the continuous degeneration and subsequent 
weakening of skeletal muscles, leading to physical disability (Yiu & Kornberg, 2008). In 
the human condition, weight bearing muscles are affected initially, with weakness 
developing in the proximal lower and then upper limbs, followed by weakness of distal 
lower and then upper limbs (Barohn et al., 1998). Patients with DMD are known to 
have elevated levels of creatine kinase within their serum. These elevated levels may 
signify impaired integrity of the muscle sarcolemma permitting the leakage of key 
enzymes out of the muscle cells (Ozawa et al., 1999; Allen & Whitehead, 2011).  
 
In patients with DMD, the diaphragm muscle is weakened due to accumulation of 
adipose and connective tissue (De Bruin et al., 1997). Force production is decreased 
(Beck et al., 2006), and patients hypoventilate (Smith et al., 1989b). Due to reductions 
in skeletal and cardiac muscle function, respiratory and heart failure are the most 
common causes of premature death in DMD (Wu et al., 2014). Hypoventilation (Smith 
et al., 1989b) and obstructive events (apnoea) often appear in patients during sleep 
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(Hill et al., 1992; Barbé et al., 1994). This can result in blood gas disturbances (Smith et 
al., 1989a) and thus sleep can be a dangerous period for patients. 
 
1.5.4 Sleep-disordered Breathing in DMD 
Obstructive sleep apnoea (OSA) is the most common form of sleep disordered 
breathing (SDB). Characteristics of this syndrome include poor performance of the 
upper airway resulting in significantly reduced (hypopnoea) or the complete cessation 
(apnoea) of airflow (Eckert & Malhotra, 2008). DMD patients with upper airway muscle 
complications are extremely susceptible to OSA. Approximately 80% of DMD patients 
suffer from SDB and display signs of hypoventilation (Barbé et al., 1994; Labanowski et 
al., 1996). 
 
Disruptions to airflow and breathing can result in blood gas disturbances such as 
hypoxaemia (low O2 in the blood) and hypercapnia (high CO2 in the blood) (Krieger et 
al., 1989). Collapse of the airway is due to a sleep-related reduction in upper airway 
muscle activity linked with consequent failure of the pharyngeal dilator muscles. These 
dilator muscles oppose the collapsing pressure that is generated by the diaphragm and 
accessory muscles during inspiration (Bradford et al., 2005). Central and peripheral 
chemoreceptors (carotid bodies) recognise blood-gas disturbance and patients are 
forced to arouse from sleep to reinstate the obstructed airway. This leads to repetitive 
hypoxia/ reoxygenation cycles and disrupted sleep. This may occur several times per 
hour during sleep. A tight relationship exists between sleep-related disturbances and 
patients with muscular disorders. It is often the case that patients suffering from sleep-
related disturbances will die at night (Barbé et al., 1994). Barbé et al., (1994) reported 
that sleep-related disturbances occur frequently in DMD patients. They suggest that 
sleep-related disturbances should be considered by physicians if diurnal arterial 
hypoxemia is present in older DMD patients.  
 
The key comorbidities associated with DMD, namely, hypertension, diabetes, oxidative 
stress, and cardiovascular disease among others are also associated with OSA. Patients 
with OSA often complain of being overtired due to their fragmented sleep patterns. A 
variety of treatment options exist in relation to OSA such as weight loss, positive airway 
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pressure, oral appliances and surgery. Continuous positive airway pressure (CPAP) is 
widely considered to be the gold standard treatment for OSA. CPAP delivers a fixed 
constant pressure on inspiration and expiration and this increase prevents airway 
collapse during inspiration.  
 
1.6 Models of Duchene Muscular Dystrophy 
A variety of dystrophic animal models exist across a broad spectrum from rodent to 
canine models such as the dystrophic golden retriever (Ambrósio et al., 2009), the 
dystrophic worm and the dystrophic zebrafish (Grounds et al., 2008). 
 
1.6.1 Dystrophin Deficient mdx Mouse 
The mdx mouse is the most widely studied animal model of DMD (Falzarano et al., 
2015). The C57BL/10ScSn-Dmdmdx/J colony arose due to a spontaneous mutation in 
the premature stop codon which terminated exon 23 of the dystrophin gene 
(Arechavala-Gomeza et al., 2010). Similar to the human condition, in mdx mice the 
dystrophin protein is not expressed (Bulfield et al., 1984). For the past three decades, 
the mdx mouse has been used extensively to test potential therapeutic strategies and 
to investigate the pathophysiology associated with muscular dystrophy. Disease 
progression in the diaphragm of the mdx mouse is relatable to the human condition 
with extensive fibrosis (Stedman et al., 1991; Gosselin & Williams, 2006) continuing 
until death (Huang et al., 2009). Mdx skeletal muscle shows repetitive cycles of 
degeneration and regeneration of muscle fibres, similar to the human condition. This 
repair initiates at 2 weeks, peaking at 12 months and continuing indefinitely. Chronic 
inflammation is evident by the infiltration of inflammatory cells in both DMD patients 
and mdx mouse peripheral skeletal muscles (Grounds et al., 2008). However, the 
extent of fibrosis and subsequent loss of function in limb muscles is less severe in mdx 
mice (Dangain & Vrbova, 1984). The reduction in the loss of functional muscle in mdx 
mice could be due to the presence and upregulation of utrophin (Falzarano et al., 
2014). In mdx mice, normal calcium homeostasis is altered, resulting in increased 
cytotoxic levels of Ca2+ in muscle cells (Fong et al., 1990; Turner et al., 1993). Repeated 
cycles of muscle degeneration and regeneration eventually lead to the exhaustion of 
satellite cells.  
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A study showed that at 8 weeks of age, there is a significant respiratory phenotype 
evident in the mdx mouse (Burns et al., 2015). Behaving mdx mice hypoventilate 
compared to control mice (Burns et al., 2015, 2017). At this young age, diaphragm 
(Burns et al., 2017b; Burns et al., 2019c) and upper airway muscle (sternohyoid) 
weakness is present in mdx mice (Burns & O'Halloran, 2016; Burns et al., 2017a). 
Studies conducted by (Mosqueira et al., 2013), examined the integrity of respiratory 
control mechanisms of mdx mice. Studies using whole-body plethysmography and 
phrenic nerve recordings showed that ventilatory chemosensory drive is blunted in 
mdx mice. Additionally, through molecular analysis of the carotid body, they showed 
that mRNA and protein expression of dystrophin is absent in carotid bodies from mdx 
mice (Mosqueira et al., 2013). Interestingly, Burns et al. (2017) describe hypoactivity 
in mdx carotid body, a sensory deficit that may explain the persistent hypoventilation 
at rest. 
 
In addition to the C57BL/10ScSn-Dmdmdx/J, the DBA/2 mdx mouse is a relatively new 
murine model of DMD. This variation of mdx mice displays a more severe dystrophic 
phenotype making it more akin to the human condition in terms of histopathology 
(Rodrigues et al., 2016). These DBA mice are shown to have a shorter life span when 
compared to other mdx models and have a more severe muscle phenotype . DBA/2 
mice also show signs of a reduction in muscle mass, increased fatty tissue accumulation 
and fibrosis (Fukada et al., 2010). Studies have investigated the effects of experimental 
sleep apnoea on cardiac and respiratory function. Upon exposure to episodic hypoxia 
(EH) (as would happen during sleep), they noticed an increase in fibrosis of both the 
diaphragm and cardiac muscle in 18-month old mice (Chaudhari et al., 2016). Their 
comprehensive study suggests that sleep apnoea and EH greatly impacts both on 








1.7 Management of DMD 
Unfortunately, there are not many therapeutic options or treatments available for this 
fatal disease. According to Yiu and Kornberg (2008) the only pharmacological 
intervention demonstrating efficacy to date are corticosteroids.  
 
1.7.1 Corticosteroids 
Prednisolone was shown to have anti-inflammatory effects in reducing macrophage, 
lymphocyte (Wehling-Henricks et al., 2004), and eosinophil expression in skeletal 
muscle (Marques et al., 2009). Mdx mice have given great insight into the positive 
effects and mechanisms of steroidal action in DMD, however, long term studies (>100 
days) have shown considerable drawbacks to long term treatment with 
corticosteroids. Steroids have been the gold standard therapy in DMD since 1974 
(Drachman et al., 1974). Although steroids may show signs of slowing the progression 
of the disease, certain side effects are also associated with administration. Side effects 
of steroidal agents include metabolic and nutritional disorders, and gastrointestinal 
symptoms. Steroidal agents have also been shown to induce fibrosis of both skeletal 
and cardiac tissue (Sali et al., 2012). Other side effects of steroidal treatment include 
short stature, obesity and cataracts (Schara et al., 2001). 
 
1.7.2 Utrophin 
An alternative therapy is the up-regulation of the utrophin protein to replace 
dystrophin. Both utrophin and dystrophin share similarities in structural organization 
and protein binding properties. Both in DMD patients and mdx mice, the expression of 
utrophin is seen to be increased naturally in order to replace the absent dystrophin. 
Utrophin expression naturally increases with age in DMD making for an adequate 
substitute for dystrophin (Guiraud et al., 2015) while also allowing for muscle repair 
through the continuity of the myotubes in mdx mice (Nakamura, 2015; Tinsley et al., 
2015). SMT C1100 is an orally administered drug developed by Tinsley, Robinson and 
Davies, (2015). This utrophin modulator has been through various successful clinical 




1.7.3 Exon Skipping 
Exon skipping is a promising genetic therapy which can restore functional dystrophin 
by coding the protein after the nonsense mutation. The use of antisense 
oligonucleotides to induce skipping of the selected exons resulted in functional 
dystrophin in mdx mice (Goyenvalle et al., 2004). However, the practical application of 
this technique has initially been problematic and use of mdx tissue has proved very 
beneficial in monitoring the therapeutic and adverse effects of genetic therapies prior 
to clinical trials (Hoen et al., 2006). Although exon skipping rescued dystrophin 
expression in mdx mice in both tibialis and extensor digitorum longus muscles, the 
effect was localised and temporary (Goyenvalle et al., 2004). Moreover, restoration of 
dystrophin expression in mdx mice resulted in an immune response to the new protein  
and low expression levels necessitated weekly intravenous administration of 20-O-
methyl phosphorothioates (Lu et al., 2005). Nonetheless, use of the mdx mouse to 
optimise delivery techniques has been more promising, using 20-O-methylmodified 
bases (AOs), which are widely used to alter premRNA processing although the duration 
of dystrophin expression was limited and expression was low (McClorey et al., 2006).  
 
1.8 Aims and Hypothesis 
Duchenne muscular dystrophy is a severe progressive muscular disorder which often 
culminates in respiratory failure and premature death. To date, there is no cure for this 
disease. At just 8 weeks of age there is evidence of a respiratory phenotype in the mdx 
model. Mdx mice display signs of muscle fibre loss and NMJ remodelling. However, 
despite severe diaphragm muscle weakness, mdx mice display signs of preserved 
breathing capacity with the ability to enhance ventilation in response to chemo-
stimulation (Burns et al., 2017). Moreover, peak inspiratory pressure-generating 
capacity is preserved in 2-month old mdx mice despite profound diaphragm weakness 
(Burns et al., 2019c). It has been suggested that neural compensatory mechanisms are 
at play in mdx mice in support of breathing capacity at least early in dystrophic disease 
(O'Halloran & Burns, 2018; Burns et al., 2019c). Moreover, the loss of compensatory 
plasticity with advancing disease may explain the development of respiratory 
insufficiency in DMD (Burns et al., 2019). The aim of this thesis was to examine 
respiratory muscle motor unit behaviour in diaphragm, intercostal and upper airway 
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muscle in the mdx mouse model of DMD. We sought to determine if there was 
evidence of adaptation in respiratory motor pathways in young mdx mice that 
compensates for established respiratory muscle weakness. 
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2.1 Ethical Approval 
Procedures on live animals were performed under licence in accordance with Irish and 
European directive 2010/63/EU following ethical approval by University College Cork 
(AEEC no. 2013/035). Experiments were carried out in accordance with guidelines laid 
down by University College Cork’s Animal Welfare Body, and conform to the principles 
and regulations described by Grundy (Grundy, 2015).  
 
2.2 Experimental Animals 
Male wild-type (WT; C57BL/10ScSnJ; n=23) and mdx (C57BL/10ScSn-Dmdmdx/J; n=23) 
mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and were 
housed at University College Cork’s animal facility. Animals were housed 
conventionally in temperature- and humidity-controlled rooms, operating on a 12 h 
light:12 h dark cycle with food and water available ad libitum. Mice were studied at 
eight weeks of age. A thorough assessment of respiratory performance was 
performed, including measurements of breathing and ventilatory capacity in response 
to chemoactivation, recordings of thoracic inspiratory pressure and respiratory muscle 
EMG in vivo and respiratory muscle functional tests ex vivo. 
 
2.3 Respiratory Flow Recordings in Conscious wild-type and mdx mice 
2.3.1 Whole-body plethysmography 
Whole-body plethysmography was used to assess respiratory flow in unrestrained, 
unanaesthetised mice. WT (n=10) and mdx (n=8) mice were introduced into 
plethysmograph chambers (Model PLY4211; volume 600ml, Buxco Research Systems, 
Wilmington, NC, USA) and were allowed an acclimation period typically lasting 40-60 
minutes, with room air passing through each chamber (1L.min-1).  
2.3.2 Experimental Protocol 
Following acclimation, during confirmed periods of quiet rest, a 20-minute baseline 
recording was performed in normoxia (FiO2 = 0.21; balance N2). This was followed by 
maximal chemoreceptor stimulation with hypercapnic-hypoxia (FiO2 = 0.10 & 6 FiCO2= 
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0.06) for 5 minutes, to examine peak ventilatory capacity. Respiratory parameters 
including respiratory frequency (fR), tidal volume (VT) and minute ventilation (VE) were 
recorded on a breath-by-breath basis for analysis offline.  
2.3.3 Data Analysis 
Baseline normoxic ventilation was determined as an average of the baseline period. 
For hypercapnic-hypoxia, ventilatory measurements were taken during the final (5th) 
minute of the challenge. VT and VE, were normalised for body mass (g).   
 
2.4 Respiratory EMG and motor unit recordings in anaesthetised mice 
2.4.1 Surgical Preparation 
Animals were anaesthetised with 5% isoflurane in 60% O2 (balance N2). Male WT (n = 
13) and mdx (n = 14) mice were immediately placed on a thermostatically-controlled 
heating blanket in the supine position and body temperature was maintained at 37°C 
as monitored via a rectal probe (Harvard Apparatus, Holliston, MA, USA). Animals were 
then weaned off isoflurane whilst urethane anesthesia was administered (1.7 g kg−1 
i.p.). Mice were maintained under urethane anesthesia for the remainder of the 
protocol. Assessment of an adequate depth of anesthesia was performed through the 
absence of the pedal withdrawal reflex in response to a noxious paw pinch. A pulse 
oximeter clip (MouseOx, Starr Life Sciences Corporation, Oakmount, PA, USA) was 
placed on the thigh of each mouse for the continuous measurement of peripheral O2 
saturation (SPO2). To avoid upper airway occlusion during surgery and throughout the 
protocol, a mid-cervical tracheotomy was performed. Using an electronic gas mixer 
(CWE Inc.), animals were maintained on supplemental O2 (FiO2 = 0.60; balance N2) via 
a bias flow over the tracheal cannula opening.  
 
2.4.2 Experimental Protocol 
Following surgical preparation, animals were allowed to stabilize for ~10 minutes. 
Next, a steady-state baseline period was recorded for 10 minutes. Next, a hypercapnic-
hypoxia (FiO2 = 0.15; FiCO2 0.06; balance N2) challenge was performed. Upon 
completion of the protocol, mice were euthanised via anaesthetic overdose.  
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2.4.3 Intramuscular EMG Recordings 
Concentric needle electrodes (26G; Natus Manufacturing Ltd, Gort, Ireland) were 
inserted into the costal diaphragm, external intercostal (T3) and genioglossus muscles 
for the continuous measurement of EMG activity and motor unit potentials. Right-
sided costal diaphragm recordings were made by blind insertion of the recording 
electrode under the lower ribcage guided by audio recording, which facilitated 
electrode placement into the muscle anchoring the beveled needle sufficiently to allow 
insertion of the recording electrode. Similarly, the intercostal electrode was placed 
using anatomical landmarks and inserted perpendicular to the ribs guided by audio 
recording.  For the genioglossus, the needle electrode was inserted just lateral to the 
lingual frenulum via the floor of the mouth into the body of the muscle, once again 
guided by audio recordings. This standardized approach typically led to the 
identification of phasic motor activity upon first placement, and thereafter subtle 
movement of the electrode, guided by audio recordings, ensured close proximity of 
the electrode to active motor units. Each signal was amplified (×5000), filtered (500 Hz 
low cut-off to 5000 Hz high cut-off) and integrated (50 ms time constant; Neurolog 
system, Digitimer Ltd, Welwyn Garden City, UK). All signals were passed through an 
analog-to-digital converter (r8/30; ADInstruments) and motor unit potentials were 
acquired using Spike2 software (Cambridge Electronic Design Limited, UK). A critical 
parameter for the acquisition of action potential waveforms is a high sampling rate. 
For these motor unit recordings, a sampling rate of 12,500Hz was used. A reference 
electrode was placed in the gastrocnemius muscle of the right hind-limb. 
 
2.4.4 Motor Unit Spike Sorting 
The objective of motor unit sorting was to take a voltage trace consisting of action 
potentials from a multiplex of myocytes and characterize distinct, phasically-active and 
reproducible single motor unit potentials. In principle, the spikes fired by a single 
neuron tend to have a particular shape mainly determined by the orientation and 
distance relative to the site of recording, and the morphology of its dendritic tree. To 
sort motor units, we adapted the method of spike-sorting algorithms which have four 




For the raw signal, spikes typically exist side-by-side with local field potentials (LFPs). 
The filtering step allowed us to separate both high and low frequency activity. To 
facilitate spike detection, a band-pass filter was used to set an amplitude threshold for 
incoming spikes. If values for the threshold were set too high, low amplitude spikes 
would be missed, and vice versa if the threshold was set too low, it would result in the 
excessive detection of false positive events e.g. background noise.  
 
2.4.4.2 Detection 
Spikes as well as background noise were visualised concurrently within the raw signal. 
To separate spikes from noise, strict detection functions were applied, and data 
windows were extracted to determine new and held units (see Table 2.1). 
 
2.4.4.3 Feature Extraction 
Principal component analysis (PCA) was used to extract features of the detected spikes. 
PCA uses orthogonal vectors to examine and display the directions of the largest 
instances of variability within the waveform. These variations are then represented as 
a linear combination of the principal components. This multifaceted and most 
commonly used approach examines features such as: (i) peak amplitude; (ii) trough 
amplitude; (iii) crest to crest trough amplitude; (iv) width; (v) rise slope; (vi) fall slope; 
(vii) energy/power/root mean squared (RMS). In principle, the greater the number of 
discriminative features examined, the better the ability to distinguish distinct spike 
shapes. 
 
2.4.4.4 Clustering Analysis  
The fourth and final step of our spike sorting algorithm was K-means clustering. K-
means clustering aims to find similarities within the data set with the variable K given 
as the number of groups. 
 
2.4.4.5 Data Analysis 
For integrated diaphragm, intercostal and genioglossus EMG activity, amplitude was 
analysed and averaged during stable baseline periods, immediately prior to and during 
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chemostimulation with hypercapnic-hypoxia. Integrated EMG activity is expressed in 
arbitrary units (AU) and was compared between WT and mdx preparations. Modal 
instantaneous firing frequencies of the discriminated active single motor units were 




Figure 2.1. Intramuscular EMG recording and spike sorting process. 
A) The electrical activity of myocytes recorded by concentric needle electrodes within the end effector muscle of interest. Blue and red motor units are within the range of 
detection and can be distinguished via offline spike sorting analysis. Black potentials are unsorted motor units which can be detected but are outside the spike sorting range. 









Section Parameter                                                      Definition                        Set value 
Forming a new template:    
 Number of similar spikes for a new template Dictates how many spikes must match each other before a template 
is promoted from provisional status to one we can see and use for sorting 
8 
 
Template width as a percentage of amplitude Modifies the initial boundaries or limits of all templates. 32 
 
No template for shapes rare than 1 in N 
If no spikes occur again within 1 in N count then the provisional template 
decays and may be deleted. This helps to avoid promoting spikes to 
‘real status’ if they are very rare. 
10 
Matching a spike to a  
template: 
   
 
Maximum percent amplitude changes for X  This helps if the spike class changes in amplitude and not shape. 0 
 
Minimum percentage of points in template 
Specifies how many data points must lie within the boundaries of the 
template. 
If more than one template fits, then spikes are matched to the template 
with 
the smallest error between the mean template and the spike  
 Template modification mode In this mode the first spike that forms the template has the most influence 
on the shape. 
Add all 
Waveform data section:  This is where we control how the raw waveform data is processed into spikes.  
 
Waveform interpolation Waveforms are shifted by fractions of a sampling interval to align them with 
templates using linear, parabolic or cubic spline interpolation. 
Cubic spline 
High-pass filter:  As a rule of thumb it should be set to approximately the width of the oscilloscope 
display. Too low a value will significantly change the spike shapes. 
2.6ms 
Remove DC offset before  
template matching: 
 This subtracts the mean level from each spike before matching. It is better to use 
the high-pass filter unless you have sudden DC shift in your baseline.  
32 
 
2.5 Ex vivo Diaphragm Muscle Function 
WT (n=10) and mdx (n=9) mice were anaesthetised with 5% isoflurane in FiO2 = 0.6 
(balance N2) followed by gradual transfer to urethane anaesthesia (1.7g/kg i.p.). 
Following an in vivo assessment of respiratory performance, mice were euthanised 
by decapitation. The diaphragm muscle (rib and central tendon intact) was 
immediately excised and placed in a tissue bath at room temperature containing 
continuously gassed hyperoxic (95% O2/ 5% CO2) Krebs solution (in mM: NaCl, 120; 
KCl, 5; Ca2+ gluconate, 2.5; MgSO4, 1.2; NaH2PO4, 1.2; NaHCO3, 25; and glucose, 11.5) 
and d-tubocurarine (25μM) prior to functional analysis. Diaphragm muscle 
preparations were suspended vertically between two platinum plate electrodes in a 
water-jacketed tissue bath at 35oC containing Krebs solution and were continuously 
gassed with hyperoxia (95% O2 & 5% CO2). The rib was attached to an immobile hook 
and the central tendon was attached to a dual-mode force transducer (Aurora 
Scientific Inc.; Aurora, ON, Canada) with non-elastic string. Muscle optimum length 
(Lo) was determined by adjusting the position of the force transducer, in turn 
adjusting the length of the muscle preparations, using a micro-positioner between 
intermittent twitch contractions (Burns & O'Halloran, 2016; Burns et al., 2017a). Lo 
was determined as the muscle length which revealed maximal isometric twitch force 
in response to a single isometric twitch stimulation (supramaximal stimulation, 1ms 
duration). Preparations remained at Lo for the duration of the protocol. 
2.5.1. Experimental Protocol 
A single isometric twitch contraction was measured. Peak isometric twitch force (Pt), 
contraction time (CT) and half-relaxation time (½ RT) were determined. The force-
frequency relationship was examined by stimulating the muscle sequentially at 10, 
20, 40, 60, 80, 100, 120, 140 and 160 Hz (300ms train duration). Contractions were 
interspersed by a 1 min interval. Next, an isotonic contraction was elicited in 
preparations at 0% load to examine maximum unloaded muscle shortening and 
velocity of shortening (Burns & O'Halloran, 2016; Burns et al., 2017a). 
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2.5.2 Data Analysis 
Muscle force was normalised for muscle cross-sectional area (CSA) and expressed as 
specific force (N.cm-2). The CSA of each muscle bundle was determined by dividing 
muscle mass (weight in grams) by the product of muscle Lo (cm) and muscle density 
(assumed to be 1.06 g.cm-3). CT and ½ RT were measured as indices of isometric 
twitch kinetics. Total muscle shortening was determined as the maximum distance 
shortened during contraction. Total muscle shortening (Smax) was determined in 
absolute units (cm) and was normalised to Lo and expressed in L.Lo-1. Shortening 
velocity (Vmax) was measured as the distance shortened during the initial 30 ms of 
shortening (Lewis et al., 2015; Lewis et al., 2016; Burns et al., 2017a) and was 
determined in absolute units (cm.s-1) and was normalised to Lo and expressed in Lo.s-
1. 
2.6 Statistical Analysis 
Data were statistically analysed by Prism 6.0 (Graphpad Software, San Diego, CA, 
USA). P<0.05 was considered to be statistically significant; this was determined a 
priori. For measures of ventilation (Table 3.1), data are shown as mean ± SD and were 
statistically compared using unpaired Student’s t test with Welch’s correction as 
appropriate, or Mann-Whitney test. For measures of EMG and motor unit properties 
(Figures 3.3, 3.4 and 3.5) data are presented as box and whisker plots (median, 25-
75 percentile and scatter plot) and were statistically compared by unpaired Student’s 
t tests or Mann-Whitney test. For measures of EMG (Figures 3.7, 3.8, 3.9) data are 
presented as box and whisker plots (median, 25-75 percentile and scatter plot) and 
were statistically compared by two-way ANOVA with Bonferroni post hoc test. For 
measures of ex vivo respiratory muscle contractile kinetics (Table 3.2) data are shown 
as mean ± SD and were statistically compared using unpaired Student’s t test with 
Welch’s correction as appropriate, or Mann-Whitney test. For measures of ex vivo 
respiratory muscle contractile force (Figure 3.11), twitch and tetanic data were 
statistically compared using unpaired Student’s t test with Welch’s correction as 
appropriate, or Mann-Whitney test. Force-frequency data were statistically 
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compared using two-way ANOVA with Bonferroni post hoc test. *P < 0.05; **P < 0.01; 
***P < 0.001; ****P < 0.0001.  
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Chapter 3: Results  
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3. Results 
3.1 Baseline Ventilation and Ventilatory Responsiveness to Hypercapnic-Hypoxia in 
Conscious Mice 
Figure 3.1 shows representative respiratory flow traces for wild-type (WT) and mdx 
mice during normoxia (FiO2 = 0.21) and hypercapnic-hypoxia (FiO2 = 0.10 & FiCO2 = 
0.06). Table 3.1 shows respiratory parameters including fR, VT and VE during baseline 
(FiO2 = 0.21) and hypercapnic-hypoxia. During baseline conditions, fR was greater in 
mdx (P = 0.0395; unpaired Student’s t test) compared with age-matched WT mice. 
Upon exposure to hypercapnic-hypoxia, VT was lower in mdx (P = 0.0343) when 
compared with WT. Minute ventilation was equivalent for both groups during 
baseline conditions. There was a trend towards a reduction in minute ventilation for 
mdx mice (P = 0.0711) during hypercapnic-hypoxia compared to WT.  
 
Figure 3.1. Respiratory flow traces. 
Representative respiratory flow traces for WT (black) and mdx (grey) mice during normoxia (FiO2 = 









Normoxia (21% O2) 
fR (brpm) 196 ± 15 211 ± 14 P = 0.0395 
VT (ml g-1 body mass) 0.007 ± 0.001 0.006 ± 0.001 P = 0.0959 
VE (ml g-1 min-1) 1.31 ± 0.15 1.28 ± 0.25 P = 0.6982 
Hypercapnic-hypoxia (FiO2 = 0.10 & FiCO2 = 0.06) 
fR (brpm) 366 ± 28 360 ± 61 P = 0.7726 
VT (ml g-1 body mass) 0.014 ± 0.002 0.011 ± 0.002 P = 0.0343 
VE (ml g-1 min-1) 5.01 ± 0.98 3.99 ± 1.24 P = 0.0711 
Body mass (g) 24.8 ± 1.5 26.1 ± 0.8 P = 0.0382 
 
Table 3.1. Breathing during normoxia and hypercapnic-hypoxia 
Group data for breathing frequency (fR), tidal volume (VT) and minute ventilation (VE) for WT (n=10) 
and mdx (n=8) mice during normoxia (FiO2 = 0.6 ; balance N2) and hypercapnic-hypoxia (FiO2 = 0.1 and 
FiCO2 = 0.06 ; balance N2). Data are shown as mean ± SD and were statistically compared using 
unpaired Student’s t test with Welch’s correction as appropriate, or Mann-Whitney test.  
 
3.2 Respiratory muscle motor unit properties  
Figure 3.2 shows a representative trace of basal motor unit properties recorded from 





Figure 3.2. GG motor unit properties in an anaesthetised wild-type mouse. 
Original traces of in vivo GG EMG and motor unit activities in anaesthetised WT mouse during baseline (FiO2 = 0.6). The bottom black trace shows an original raw GG recording, 
with the integrated signal directly above. Both blue and green motor units were discriminated from the raw GG signal. Motor units are separated out showing their 
corresponding instantaneous firing frequencies.  
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3.2.1 Diaphragm   
Diaphragm EMG activity during baseline was significantly lower in mdx (Fig. 3.3A; P = 
0.0031; unpaired Student’s t test) mice compared to WT. The number of diaphragm 
motor units active during baseline was significantly increased for mdx (Fig. 3.3.B; P = 
0.0075; unpaired Student’s t test) compared to WT. The instantaneous firing 
frequency (IFF) of diaphragm motor units was lower for mdx (Fig. 3.3C; P = 0.064; 
Mann-Whitney test) compared to WT.  
 
Figure 3.3. Diaphragm EMG and motor unit properties for anaesthetised mice 
during baseline conditions.  
Group data for diaphragm EMG and motor unit properties for WT and mdx mice during baseline (FiO2 
= 0.6). A, B and C: Diaphragm EMG activity (A; amplitude), the number of active diaphragm motor 
units (B) and diaphragm instantaneous firing frequency (IFF) during baseline. Data are presented as 
box and whisker plots (median, 25-75 percentile and scatter plot) and were statistically compared by 
unpaired Student’s t tests or Mann-Whitney test. 
  
Diaphragm 
A) B) C) 
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3.2.2 External Intercostal 
External intercostal EMG activity during baseline was unchanged between WT and 
mdx mice (Fig. 3.4A; P = 0.9235; Mann-Whitney). The number of intercostal motor 
units active and the IFF of intercostal motor units were equivalent between WT and 
mdx mice (Fig. 3.4B & C; P = 0.9323 and P = 0.7867; unpaired Student’s t test and 
Mann-Whitney; number of active units and IFF, respectively).  
 
Figure 3.4. External intercostal EMG and motor unit properties for anaesthetised 
mice during baseline conditions.  
Group data for external intercostal EMG and motor unit properties for WT and mdx mice during 
baseline (FiO2 = 0.6). A, B and C: External intercostal EMG activity (A; amplitude), the number of active 
external intercostal motor units (B) and external intercostal instantaneous firing frequency (IFF) during 
baseline. Data are presented as box and whisker plots (median, 25-75 percentile and scatter plot) and 





















































P  =  0 .7 8 6 7
External Intercostal 
A) B) C) 
 41 
3.2.3 Genioglossus 
GG EMG activity during baseline was equivalent between WT and mdx mice (Fig. 
3.5A; P = 0.9173; Mann-Whitney test). The number of GG motor units active during 
baseline was significantly increased for mdx (Fig. 3.5B; P = 0.019; Mann-Whitney test) 
compared to WT. Furthermore, no difference was observed for GG IFF between 
groups (Fig. 3.5C; P = 0.7761; Mann-Whitney).  
 
Figure 3.5. GG EMG and motor unit properties for anaesthetised mice during 
baseline conditions.  
Group data for GG EMG and motor unit properties for WT and mdx mice during baseline (FiO2 = 0.6) 
A, B and C: GG EMG activity Amplitude (A), the number of active GG motor units (B) and GG 
instantaneous firing frequency (IFF) (C) during baseline. Data are presented as box and whisker plots 
(median, 25-75 percentile and scatter plot) and were statistically compared by Mann-Whitney test. 
 
 
3.3 Respiratory Muscle EMG Activity in Anaesthetised Mice During Baseline and 
Chemostimulation  
Figure 3.6 shows representative original traces for diaphragm, intercostal and GG 
EMG activities during baseline (FiO2 = 0.6) and chemostimulation with hypercapnic-
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Figure 3.6. Diaphragm, intercostal and GG EMG activity in anaesthetised mice. 
Original traces of diaphragm (Dia - bottom 2 traces), intercostal (IC - middle 2 traces) and GG (top 2 traces) EMG activities in anaesthetised WT (black) and mdx (grey) mice 
during baseline (FiO2 = 0.6). For each muscle, the bottom trace shows an original raw recording, with the integrated signal directly above.
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Chemostimulation with hypercapnic-hypoxia resulted in an increase in diaphragm 
(Fig. 3.7; P < 0.0001; repeated measures two-way ANOVA), intercostal (Fig. 3.8; P < 
0.0001) and GG (Fig. 3.9; P = 0.0573) EMG activity. During hypercapnic-hypoxia, 
diaphragm EMG activity (amplitude) was significantly lower for mdx (Fig. 3.7; P < 
0.05; repeated measures two-way ANOVA with Bonferroni post hoc test) compared 
to WT. During baseline and hypercapnic-hypoxia, external intercostal EMG activity 
was equivalent between WT and mdx mice (Fig. 3.8; P = 0.4674; two-way ANOVA 
(genotype)). Similarly, GG EMG activity was equivalent between WT and mdx mice 
(Fig. 3.9; P = 0.5304; two-way ANOVA (genotype)) during baseline and 
chemoactivation (hypercapnic-hypoxia).  
 
 
Figure 3.7. Diaphragm EMG activity in anaesthetised mice during baseline and 
hypercapnic-hypoxia. 
Group data for diaphragm EMG activity during baseline (FiO2 = 0.6) and chemostimulation with 
hypercapnic-hypoxia (FiO2 = 0.15 / FiCO2 = 0.06). Data are presented as box and whisker plots (median, 
25-75 percentile and scatter plot) and were statistically compared by two-way ANOVA with Bonferroni 




Figure 3.8. External intercostal EMG activity in anaesthetised mice during baseline 
and hypercapnic-hypoxia. 
Group data for external intercostal EMG activity during baseline (FiO2 = 0.6) and chemostimulation 
with hypercapnic-hypoxia (FiO2 = 0.15 / FiCO2 = 0.06). Data are presented as box and whisker plots 
(median, 25-75 percentile and scatter plot) and were statistically compared by two-way ANOVA with 




Figure 3.9 GG EMG activity in anaesthetised mice during baseline and 
hypercapnic-hypoxia. 
Group data for GG EMG activity during baseline (FiO2 = 0.6) and chemostimulation with hypercapnic-
hypoxia (FiO2 = 0.15 / FiCO2 = 0.06). Data are presented as box and whisker plots (median, 25-75 




3.4 Diaphragm Muscle Contractile Function ex vivo 
Figure 3.10 shows representative original traces for diaphragm muscle twitch (A) and 
tetanic (B) contractions, force-frequency relationship (C) and maximum unloaded 
shortening (D). Table 3.2 shows data for twitch contractile kinetics (CT and ½ RT) and 
isotonic contractile kinetics (Smax and Vmax) of diaphragm muscle preparations from 
WT and mdx mice. Diaphragm CT and ½ RT were equivalent in WT and mdx 
preparations. Absolute values for Smax and Vmax were lower in mdx (P = 0.0003 and P 
= 0.0117 respectively; unpaired Student’s t test and Mann-Whitney test) diaphragm 
preparations compared with WT. Normalised values for Smax and Vmax were 
equivalent in both groups. 
 
 
Figure 3.10. Ex vivo diaphragm muscle contractions. 
A-D: original traces of ex vivo diaphragm muscle twitch contraction (A), tetanic contraction (B), 
maximum unloaded shortening (C) and force-frequency relationship (D) for WT (black) and mdx 














Table 3.2. Ex vivo respiratory muscle contractile kinetics. 
Definition of abbreviations: ½ RT, half-relaxation time; CT, contraction time; Lo, optimum length; Smax, 
maximum unloaded shortening; Vmax, maximum shortening velocity. Data are shown as mean ± SD 
and were statistically compared using unpaired Student’s t test with Welch’s correction as 





(n = 10) 
mdx 
(n = 8-9) 
P value 
CT (ms) 17.2 ± 2.6 18.1 ± 4.0 P = 0.5875 
½ RT (ms) 19.9 ± 6.9 21.7 ± 9.0 P = 0.6357 
Smax (cm) 0.39 ± 0.08 0.23 ± 0.06 P = 0.0003 
Smax (L Lo-1) 0.37 ± 0.06 0.31 ± 0.08 P = 0.0772 
Vmax (cm s-1) 4.1 ± 1.0 2.3 ± 1.2 P = 0.0117 
Vmax (Lo s-1) 4.0 ± 1.0 3.2 ± 1.7 P = 0.237 
Lo (cm) 1.1 ± 0.1 0.8 ± 0.1 P = 0.0003 
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Diaphragm twitch force was lower in mdx (Fig. 3.8A Pt; P = 0.013; Mann-Whitney test) 
compared with WT. Diaphragm tetanic force at 100 Hz was lower in mdx (Fig. 3.8B, 
Po; P < 0.0001; Mann-Whitney test) compared with WT. For the force-frequency 
relationship, diaphragm specific force was reduced in mdx compared with WT 
preparations (Fig. 3.8B; P < 0.0001; repeated measures two-way ANOVA). Post hoc 
analysis revealed differences between WT and mdx diaphragm across a broad 
stimulus range (40-160 Hz).  
 
Figure 3.11. Ex vivo diaphragm muscle contractile force. 
A & B, group data (mean ± SD) for ex vivo diaphragm muscle twitch (A; Pt), tetanic (A; Po) and force-
frequency relationship (B) for wild-type (WT; black) and mdx (grey) muscle preparations. Twitch and 
tetanic data were statistically compared using unpaired Student’s t test with Welch’s correction as 
appropriate, or Mann-Whitney test. Force-frequency data were statistically compared using two-way 




































The major findings of this thesis include: (1) diaphragm muscle function is severely 
impaired in young mdx mice; (2) despite substantial diaphragm muscle weakness, 
freely-behaving mdx mice can increase ventilation during chemostimulation with 
hypercapnic-hypoxia, indicating a significant ventilatory reserve; (3) motor unit 
recordings revealed altered motor unit properties for mdx mice as evidenced by an 
increase in the number of active units for diaphragm and genioglossus muscle (but 
not intercostal) and a reduction in the instantaneous firing frequency for diaphragm 
motor units compared to WT; and (4) diaphragm EMG activity was depressed in mdx 
mice during baseline and maximum chemostimulation, compared to WT.  
 
Dystrophin is a cytoskeletal protein important for stabilizing the muscle sarcolemma. 
DMD is an X-linked recessive disorder which occurs due to mutation in the dystrophin 
gene. DMD initially manifests as muscle weakness due to a lack of expression of 
dystrophin protein (Yiu & Kornberg, 2008). In healthy muscle, dystrophin has a 
structural role in supporting muscle fibres during repeated cycles of muscle 
contraction, acting to limit the mechanical stress applied to muscle fibres (Ervasti & 
Campbell, 1991; Petrof et al., 1993). In the absence of dystrophin, such as in DMD, 
skeletal muscle fibres have increased fragility resulting in fibre damage. Common 
pathological features of dystrophic muscle include myonecrosis, inflammation and 
oxidative stress (Deconinck & Dan, 2007; Petrillo et al., 2017). Due to profound 
muscle weakness and damage, children with DMD have difficulty with ambulation in 
their early years, necessitating assistive devices.  
 
In addition to dystrophin’s role in muscle, dystrophin expression has been 
demonstrated in neuronal populations within regions such as the hippocampus 
(Lidov, 1996). Interestingly, the expression of dystrophin was reported in the carotid 
bodies of WT mice and absent within the carotid body of mdx mice (Mosqueira et al., 
2013). Despite dystrophin expression within the central nervous system, it is unclear 
if the neuromuscular control of dystrophic muscle is affected in individuals with 
DMD. Moreover, dystrophin has an important role in stabilizing the motor end plate 
(Pratt et al., 2015).  
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A pathological feature of DMD includes respiratory muscle weakness, resulting in 
compromised respiratory function. Reductions in forced vital capacity (Mayer et al., 
2015; Meier et al., 2017) and impaired inspiratory muscle strength are evident from 
a young age in DMD (De Bruin et al., 1997; Khirani et al., 2014). Respiratory system 
morbidity occurs in DMD due to weakness of the respiratory musculature (Khirani et 
al., 2014; LoMauro et al., 2017), the end effectors of breathing. Adequate respiratory 
muscle performance is essential for ventilation and mechanical manoeuvres 
including coughing and sneezing, and other protective mechanisms which safeguard 
against airway collapse. Inspiratory muscle strength declines with increasing age in 
DMD boys (Khirani et al., 2014). Individuals with DMD are predisposed to an 
increased risk of respiratory disturbance during sleep, including hypoventilation 
(Smith et al., 1989b; Kirk et al., 2000) and central and or obstructive apnoeic events 
(Khan & Heckmatt, 1994; Suresh et al., 2005; LoMauro et al., 2017). Many DMD 
patients require ventilatory support during sleep to maintain blood gas homeostasis 
to prevent oxygen desaturation from occurring. Cough and airway clearance 
manoeuvres are compromised in DMD due to reduced respiratory muscle strength, 
such that patients are more susceptible to aspiration pneumonia (Toussaint et al., 
2016). 
 
The mdx mouse is a dystrophin-deficient animal model of DMD. Skeletal muscle 
weakness occurs in mdx mice. Studies of the respiratory system in the mdx mouse 
have documented profound diaphragm muscle weakness and structural remodelling 
from a young age as a consequence of dystrophin deficiency (Stedman et al., 1991; 
Coirault et al., 1999; Coirault et al., 2003; Burns et al., 2017c; Burns et al., 2019c). 
Structural changes include muscle fibres undergoing inflammatory cell infiltration, 
fibrosis and necrosis (Gayraud et al., 2007; Ishizaki et al., 2008; Huang et al., 2011). 
Inflammatory markers such as cytokine concentrations are increased in mdx 
diaphragm, as well as the abundance of collagen deposits (Burns et al., 2018; Burns 
et al., 2019a). Moreover, indices of oxidative stress including lipid peroxidation and 
superoxide levels are elevated in mdx diaphragm compared with control muscle 
(Moraes et al., 2015). Inflammation and high levels of reactive oxygen species (ROS) 
can culminate in skeletal muscle damage leading to poor physiological performance 
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(Reid, 2001). Impaired pharyngeal muscle function (sternohyoid) has been described 
in mdx mice ( Attal et al., 2000b; Burns & O'Halloran, 2016). Preserved diaphragm 
function and endurance is essential for performing ventilatory and non-ventilatory 
behaviors including coughing and sneezing (Sieck & Fournier, 1989). Moreover, 
adequate performance of the upper airway musculature is essential to maintain 
upper airway patency and to prevent collapse of the airway and disruption to airflow, 
that can lead to blood-gas disturbances.  
 
Recent studies from our group have indicated altered sensory and motor control of 
dystrophic respiratory muscles in mdx mice (Burns et al., 2017b; Burns et al., 2019c). 
Our recent study reported lower diaphragm EMG activity in anaesthetised mdx mice 
during near maximal activation of the diaphragm (Burns et al., 2019c). Moreover, we 
revealed a relative hypo-activity of the carotid body in mdx mice, which may 
influence eupnoeic breathing (Burns et al., 2017b; Burns et al., 2019b). Depressed 
diaphragm EMG activity during near-maximal activation in mdx mice is likely 
reflective of diaphragm neuromuscular junction impairment (Pratt et al., 2015; van 
der Pijl et al., 2016) and combined with intrinsic diaphragm muscle weakness reveals 
a major functional deficit in the diaphragm in muscular dystrophy.  
 
In the current study, diaphragm muscle weakness in young mdx mice was evidenced 
by reduced twitch and tetanic force, consistent with previous reports in young and 
older mdx mice (Stedman et al., 1991; Coirault et al., 2003; Burns et al., 2017b; Burns 
et al., 2018; Burns et al., 2019c). Specific force was reduced within the frequency 
range of 40-160 Hz for mdx diaphragm compared with WT. This frequency range 
corresponds to a broad range of ventilatory and non-ventilatory behaviours (Sieck et 
al., 2013; Mantilla et al., 2014; O'Halloran & Burns, 2018; Burns et al., 2019c).  Smax 
and Vmax are lower in mdx and this is consistent with increased fibrosis within the 
diaphragm of mdx mice. Structural abnormalities occur in dystrophic muscle as a 
consequence of dystrophin deficiency and is further compounded by cycles of muscle 
fibre damage. Our previous study confirmed structural alterations in mdx diaphragm, 
including a substantial increase in the number of centralised myonuclei (measure of 
fibre regeneration following damage), increased expression of embryonic myosin 
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MyHCEMB and increased collagen content (fibrosis) (Burns et al., 2019a). These 
observations are consistent with and extend our previous findings (Burns et al., 
2017b; Burns et al., 2018) and those of others (Barros Maranhão et al., 2015; Gutpell 
et al., 2015), revealing substantial diaphragm muscle pathology in young (8 week old) 
mdx mice.  
 
Breathing was assessed using whole-body plethysmography in conscious mice during 
baseline (FiO2 = 0.21) and chemoactivated breathing with hypercapnic-hypoxia (FiO2 
= 0.10 and FiCO2 = 0.06). These assessments confirmed the capacity for mdx mice to 
enhance ventilation as previously described (Burns et al., 2017c; Burns et al., 2019c). 
Hypercapnic hypoxia is commonly used as a respiratory stimulant in studies utilizing 
pre-clinical models, including models of neuromuscular diseases such as DMD (Seven 
et al., 2018; Burns et al., 2019c). Hypoxia activates peripheral chemoreceptors 
(carotid bodies) and carbon dioxide activates both central and peripheral 
chemoreceptors, all of which leads to enhanced respiratory motor output (Kumar & 
Prabhakar, 2012). In response to hypercapnic-hypoxia, WT and mdx mice elevated 
ventilation by increasing respiratory frequency and tidal volume. Tidal volume 
generation during hypercapnic-hypoxia was lower in mdx compared with WT. 
Nevertheless, these experiments confirmed the capacity for mdx mice to boost 
ventilation in response to chemostimulation, consistent with our previous studies 
which examined the hypoxic and hypercapnic ventilatory response in young mdx 
mice (Burns et al., 2017b; Burns et al., 2019c). Interestingly, others have reported a 
loss of ventilatory responsiveness to hypercapnia with increasing age in mdx mice, 
suggesting a progressive decline in respiratory system function with disease 
progression (Gosselin et al., 2003; Huang et al., 2011; Mosqueira et al., 2013). 
 
Respiratory plasticity can be defined as the persistent change in the respiratory 
neural control network based on a prior experience (Mitchell & Johnson, 2003; 
Johnson & Mitchell, 2013). At both human and animal level, a respiratory breath is 
still achievable against all the odds  despite significant neuropathology and 
compromised phrenic motor output. This suggests that compensatory strategies may 
be at play in order to preserve breathing capacity. Nichols and Mitchell suggest that 
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this may be a multi-faceted approach employed by the CNS: 1) Enhanced central 
drive to functioning motor neurons 2); active plasticity within said neurons; 3) 
enhanced plasticity at the level of the NMJ; and 4) alteration of demand from 
diaphragm to less-used respiratory motor pools (Nichols et al., 2013). 
 
Neuromuscular control of respiratory muscle contraction is ultimately dependent on 
respiratory muscle motor units. Our study is the first to assess the activity of 
respiratory muscle motor units in mdx mice. We recorded motor unit activity of the 
diaphragm, external intercostal and genioglossus muscles. We observed altered 
motor unit properties of the diaphragm compared to WT. This was evidenced by an 
increase in the number of active units, coupled with a lower instantaneous firing 
frequency. This is consistent with assessments of the myosin heavy chain (MyHC) 
isoform composition of diaphragm muscle samples from mdx mice (Burns et al., 
2018). These studies demonstrate a reduction in the number of diaphragm fibres 
expressing MyHC IIx and IIb. This reduction is coupled with an increase in the number 
of diaphragm fibres expressing MyHC I and IIa, indicating a higher number of 
oxidative fibres. For healthy neuromuscular systems, an increase in the number of 
active diaphragm motor units typically occurs during ventilatory challenge such as 
chemoactivated breathing i.e. motor unit recruitment. In disease states such as DMD, 
an increase in the number of active motor units during baseline conditions may 
indicate compensation within the respiratory neuromuscular system acting to 
facilitate adequate ventilation. An increase in the number of active diaphragm motor 
units would lead to relatively greater activation of mdx diaphragm muscle and may 
be reflective of sprouting and re-innervation of remodelled dystrophic muscle. 
 
We anticipated that respiratory compensation in dystrophic disease would be 
characterised by an increase in the instantaneous firing frequency of mdx diaphragm 
during baseline. Such plasticity is observed to maintain respiratory performance in 
spinal cord injury (Nguyen et al. 2020). Unexpectedly, we observed a slight reduction 
in the instantaneous firing frequency of diaphragm motor units, which could occur 
for a number of different reasons: (1) a reduction in neural drive; (2) impaired 
transmission across the neuromuscular junction; and (3) a change in motor neuron 
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morphometry. Whatever the mechanism, this alteration in motor unit behavior is 
likely maladaptive. Whereas an increase in the number of active diaphragm motor 
units is beneficial to muscle contraction, the overall magnitude of diaphragm EMG 
activity in mdx mice was significantly decreased. This suggests that small motor units 
dominate the composite EMG recording in mdx mice, which in turn signifies the loss 
of large motor units (and failure to recruit large motor units during 
chemostimulation). This interpretation is consistent with the loss of large myofibres 
in mdx diaphragm. Collectively, we conclude that neuromuscular control of the 
diaphragm is impaired in dystrophic disease, with changes presenting as early as 8 
weeks in the mdx mouse. 
 
Despite neuromuscular structural remodelling, profound muscle weakness, and 
lower EMG activity in mdx diaphragm, inspiratory pressure-generating capacity is 
remarkably preserved across ventilatory (chemoactivated breathing and augmented 
breaths) and non-ventilatory behaviours (sustained tracheal occlusion) (Burns et al., 
2019c), revealing a role for accessory and auxiliary muscles in support of peak 
inspiratory pressure generation in dystrophic disease (Burns et al., 2019b). 
Interestingly, a recent study by Barnard et al., (2019) assessed respiratory muscle 
quality and function in DMD using magnetic resonance imaging (MRI) and their 
findings were surprising (Barnard et al., 2019). They demonstrated signs of minimal 
visible fatty infiltration in the intercostal muscles of DMD patients. This is one of the 
first cases whereby intercostal muscle sparing has been reported in DMD. 
 
With respect to the external intercostals in this study, there was no observed 
difference between WT and mdx animals in terms of EMG activity and motor unit 
properties. At baseline, the EMG amplitude, number of active motor units and 
instantaneous firing frequencies of these units were equivalent in WT and mdx. 
Further to this, upon chemostimulation, the EMG activity was also similar comparing 
the two genotypes. The lack of difference between WT and mdx suggests that there 
may be a greater reliance on the external intercostals for breathing given that 
diaphragm EMG (and force) is impaired. However, of note, Burns et al. (2019) showed 
that maximum external intercostal activity during airway obstruction is reduced in 
 55 
mdx compared with WT suggesting that compensatory activity in mdx that preserves 
peak inspiratory pressure generating capacity is not facilitated by the external 
intercostal muscles, suggesting a role for other auxiliary muscles such as the scalenes, 
sternocleidomastoids and trapezius muscles. 
 
This study has also shown that EMG activity of the GG is equivalent in control and 
mdx animals, yet the number of active units is different, but instantaneous firing 
frequencies of units were equivalent. This suggests that central drive to the GG is 
normal in mdx, but motor unit morphometry is changed, similar to diaphragm and 
probably a consequence of reinnervation of damaged muscle. In response to 
chemostimulation, the GG EMG response was equivalent between control and mdx 
animals suggesting a functioning capacity for mdx to preserve neural control of the 
upper airway at least in early disease. Despite preserved EMG response to chemo-
challenge in mdx mice, upper airway muscle weakness has been previously 
demonstrated in mdx (Burns 2016, Attal 2000), which may have implications for the 
maintenance of airway patency. It would be interesting to determine if GG EMG 
activity in response to upper airway occlusion is altered in mdx mice, which would 
suggest increased vulnerability to airway collapse, a substrate for the development 
of OSA. 
 
This thesis examined breathing, respiratory muscle EMG activity and respiratory 
muscle motor unit behavior in the mdx mouse model of DMD. In conclusion, the 
severe mechanical disadvantage of the diaphragm is evident across a range of 
stimulations, yet there is a preserved capacity to raise ventilation in young mdx mice. 
Motor unit remodeling is evident in the diaphragm of mdx mice, but ultimately 
diaphragm EMG activity is impaired. The combination of reduced neural activation 
of the diaphragm and intrinsic weakness reveals major compromise in the 
neuromuscular function of the diaphragm in mdx mice, early in disease progression. 
In contrast, external intercostal motor units and EMG are relatively spared at this age 
across the ventilatory range, although reduced EMG activity has been observed at 
this early stage of dystrophic disease in response to maximum activation (Burns et 
al., 2019). The novel observations in this thesis coupled with other work by our group 
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(Burns et al., 2019c) suggest that contributions from accessory muscles is critical to 
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